Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

585
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
585
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

884
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
884
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

414
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
414
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

814
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
814
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

414
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
414
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

428
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
428

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reframing ontology fact acquisition during large language model fine-tuning as a time-to-event process.

Frontiers in artificial intelligence·2026
Same author

Ecological strategies and extinction risk in butterflies and macro-moths of Great Britain and Ireland: A trait similarity network approach.

PloS one·2026
Same author

From memorization to generalization: fine-tuning large language models for biomedical term-to-identifier normalization.

Frontiers in digital health·2026
Same author

EPR26-162: Distinct Clinical Profiles of Younger and Older Patients at Risk for Non-Small Cell Lung Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Efficient and interpretable DNA/RNA representation using Komlós-Hadamard transforms.

BMC bioinformatics·2026
Same author

EPR26-162: Distinct Clinical Profiles of Younger and Older Patients at Risk for Non-Small Cell Lung Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Jan 3, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Biomarker discovery in inflammatory bowel diseases using network-based feature selection.

Mostafa Abbas1, John Matta2, Thanh Le3

  • 1Qatar Computing Research Institute, Hamad Bin Khalifa University, Doha, Qatar.

Plos One
|November 23, 2019
PubMed
Summary

Network-Based Biomarker Discovery (NBBD) effectively identifies inflammatory bowel disease (IBD) biomarkers from metagenomics data. This approach is particularly useful for small sample sizes, offering a competitive alternative to traditional methods.

More Related Videos

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.7K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.4K

Related Experiment Videos

Last Updated: Jan 3, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.7K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.4K

Area of Science:

  • Metagenomics
  • Bioinformatics
  • Computational Biology

Background:

  • Inflammatory Bowel Disease (IBD) diagnosis relies on invasive methods.
  • Metagenomics offers potential for non-invasive IBD biomarker discovery.
  • Early diagnosis of IBD is crucial for effective management.

Purpose of the Study:

  • To develop and evaluate an integrative Network-Based Biomarker Discovery (NBBD) approach.
  • To compare NBBD with traditional feature selection methods for IBD biomarker identification.
  • To assess the impact of sample size on biomarker discovery performance.

Main Methods:

  • Integrated network analysis and machine learning techniques.
  • Applied NBBD to pediatric IBD metagenomics biopsy samples.
  • Compared NBBD with Random Forest Feature Importance (RFFI) and other methods across varying data sizes.

Main Results:

  • NBBD demonstrated competitive performance against state-of-the-art methods like RFFI.
  • NBBD proved highly effective in identifying IBD biomarkers with limited sample data.
  • The performance of predictive models varied with the size of the dataset used for discovery.

Conclusions:

  • NBBD is a robust framework for identifying metagenomic biomarkers for IBD.
  • NBBD offers advantages in biomarker discovery, especially when dealing with small datasets.
  • This approach supports the development of non-invasive diagnostic tools for IBD.